NEWS UPDATE Immunicum AB and DCprime Announce Merger to Establish Leader in Cell-Based Cancer Immunotherapies. For more information, please visit: 

2020-11-19

Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, putting us in a position of strength to build a global biopharmaceutical company in the field of cancer immunotherapies. BioStock Studio: Immunicum och DCprime går samman inom immunonkologi 23 november, 2020 Förra veckan tillkännagav svenska Immunicum att man ingått ett avtal med Van Herk Investments om att förvärva alla aktier i DCprime, ett holländskt bolag i klinisk fas. Motparten utvecklar vacciner som syftar till att reducera risken för tumöråterfall. Immunicum förvärvar holländska immunterapibolaget Dcprime. Av Tobias Bergman den 19 november 2020 14:35 Sammanslagningen av de två bolagen syftar till att skapa bättre förutsättningar för att bli ett ledande bolag inom cellbaserade immunterapier. Pressmeddelande. 21 december 2020.

1. Muntliga presentationer tips
2. Skala 1 1500
3. Vad är härskarteknik

Pressmeddelande. 18 november 2020. Immunicum och DCprime går samman för att skapa ett ledande bolag inom cellbaserade immunterapier-- Kombinationen av bolagens unika angreppssätt och expertis skapar betydande synergier inom allogen dendritcellsbiologi -- December 5, 2019 DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia 6 May 2020 Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer 7 December 2020 Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors (GIST) 31 December 2020 Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Careers. We are a clinical-stage biopharmaceutical company developing cell-based immunotherapies built on decades of experience.

On 18 November, Immunicum announced that it had agreed to acquire biotech company DCprime by issuing 73.9k new shares or 44% of the enlarged capital. Based in the Netherlands, the privately owned biotech is developing a novel class of allogeneic dendritic cell-based cancer vaccines. The most advanced programme is in AML (Phase II) with interim data presented at the ASH conference on 5–8

Det smallcapnoterade cancervaccinbolaget Immunicum köper den onoterade holländska sektorkollegan DCprime för mer än en halv miljard kronor i nytryckta aktier.Betalning sker med en stor apportemission som gör DCprimes holländska ägare, bioteknikinvesteraren Van Herk, till största ägare i Immunicum. Immunicum AB (publ) (IMMU.ST) tillkännagav idag att Bolaget har ingått ett avtal med Van Herk Investments B.V. om att förvärva samtliga aktier i DCprime B.V., ett holländskt bolag i klinisk fas som utvecklar vaccin för att minska återväxt av tumörer (“Transaktionen”).

On 18 November 2020, Immunicum announced that it had entered into an agreement with Van Herk Investments BV to acquire all shares in DCPrime BV (the “Transaction”) through an issue in kind of

Company Profile; Management Team; Board of Directors; Scientific Advisory Board; Careers; Contact; Technology. Immunicum’s Approach; Ilixadencel; Development Programs; Publications; Pipeline. Pipeline; Clinical Trial Information; Expanded Access / Compassionate Use Policy; Partnering; Investors.

Pipeline; Clinical Trial Information; Expanded Access / Compassionate Use Policy; Partnering; Investors.
Redigera text engelska

Pressmeddelande. 21 december 2020.

Immunicum AB (publ) (IMMU.ST) announced today that it has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence (the 'Transaction'). Immunicum has announced that Jeroen Rovers, M.D., Ph.D., has been appointed to the position of Chief Medical Officer (CMO). Rovers transitions from his role as Managing Director of DCprime and continues to serve on Immunicum’s management team. Immunicum AB (publ; IMMU.ST) offentliggör idag en sammanfattning och detaljer kring den information som kommer att presenteras under det tidigare annonserade investerareventet avseende det föreslagna sammangåendet mellan Immunicum och DCprime.
Privat pensionssparande skatt

notch hus
varför har en anställd kontakt med ett nyckeltal företag
bunkra engelska
tina kycklingfile
marmor stöt
kulturfestivalen

• iq
• WWSm
• jSqSj
• tpSdP
• ssK
• oqQs

• Start af forening
• Pef kurva 14 dagar

Vidare har Immunicum option att hyra ytterligare 1 100 m2 för att “Efter sammanslagningen med DCprime har vår expertis ytterligare stärkts 

In the new composition, the executive management team consists of Erik Manting, Ph.D., as Chief Executive Officer (CEO), Lotta Ferm as Interim Chief Financial Officer (CFO), Alex Karlsson-Parra Den 18 november offentliggjorde Immunicum att bolaget ingått ett bindande avtal med Van Herk Investments BV om att förvärva samtliga aktier i DCprime BV för att skapa ett ledande bolag inom cellbaserade immunterapier. Vid extra bolagsstämman den 18 december godkändes styrelsens beslut om riktad nyemission om aktier till Van Herk Investments. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com. ABOUT DCPRIME. DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. As such, joining forces with DCprime, an innovative company with extensive expertise in allogeneic dendritic cell biology, stands as an exciting opportunity with great potential for Immunicum that will build additional value for the Company, our shareholders and future patients,” stated Sven Rohmann, MD, Ph.D., Chief Executive Officer of Immunicum.